Your browser doesn't support javascript.
loading
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.
Stark, Mitchell S; Klein, Kerenaftali; Weide, Benjamin; Haydu, Lauren E; Pflugfelder, Annette; Tang, Yue Hang; Palmer, Jane M; Whiteman, David C; Scolyer, Richard A; Mann, Graham J; Thompson, John F; Long, Georgina V; Barbour, Andrew P; Soyer, H Peter; Garbe, Claus; Herington, Adrian; Pollock, Pamela M; Hayward, Nicholas K.
Afiliação
  • Stark MS; Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • Klein K; Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; Clinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
  • Weide B; Department of Dermatology, University Medical Center, Tubingen, Germany.
  • Haydu LE; Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
  • Pflugfelder A; Department of Dermatology, University Medical Center, Tubingen, Germany ; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia.
  • Tang YH; Surgical Oncology Group, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia.
  • Palmer JM; Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
  • Whiteman DC; Cancer Control Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
  • Scolyer RA; Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
  • Mann GJ; Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
  • Thompson JF; Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
  • Long GV; Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
  • Barbour AP; Surgical Oncology Group, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia.
  • Soyer HP; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia.
  • Garbe C; Department of Dermatology, University Medical Center, Tubingen, Germany.
  • Herington A; School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • Pollock PM; School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • Hayward NK; Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
EBioMedicine ; 2(7): 671-80, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26288839
ABSTRACT
The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are < 15%. Hence, melanoma detection in earlier stages (stages I-III) maximises the chances of patient survival. We measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III; n = 76 and IV; n = 10) and serum samples (collected from controls with no melanoma, n = 130; and patients with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and Germany. In melanoma tissues, members of the 'MELmiR-17' panel were found to be predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7) detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (≥ 82%) when ≥ 4 miRNAs were expressed. Moreover, the 'MELmiR-7' panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood = 11, p < 0.001). This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease (stages IIIa-c/IV M1a-b) to detect relapse following surgical or adjuvant treatment.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / MicroRNAs / Melanoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / MicroRNAs / Melanoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article